BELMONT, CA--(Marketwired - November 14, 2013) - PowerVision, an innovative company focused on developing the first "true" accommodating intraocular lens, will be presenting at a showcase for private device companies at the Fifth Annual Ophthalmology Innovation Summit @ AAO taking place on November 14, 2013 at the Sheraton New Orleans in New Orleans, LA. President, CEO and Co-Founder of PowerVision, Barry Cheskin, is scheduled to present at 8:25 a.m. CST.
"We are honored and excited to present our work toward developing the FluidVision® lens, at the Ophthalmology Innovation Summit," said Mr. Cheskin. "FluidVision holds the potential to restore accommodative function to millions of patients suffering from cataracts and presbyopia, which represents a multi-billion dollar market opportunity. Restoring true accommodation requires two things: one is giving patients the ability to see near, far and anywhere in between; the other is maintaining the natural mechanism of accommodation. We believe we are the first and only company to be able to deliver true accommodation. We are preparing to initiate a multi-center CE Mark trial in early 2014 and subsequent studies in the United States afterward."
Accommodation is the eye's ability to adjust to see across a range of distances. The natural human lens does this by getting thinner or thicker. Various conditions of the eye, including cataracts and presbyopia, result in the loss of accommodative ability. Conventional IOLs lack the ability to accommodate. The FluidVision foldable intraocular lens (IOL) efficiently harnesses natural muscular forces in the eye to displace fluid in the lens, changing its shape and increasing or decreasing the power of the lens to successfully restore accommodation. The FluidVision lens is paired with the novel PowerJect™ "injector," which utilizes a unique fluid-based method of delivering the lens into the capsular bag with no change to the surgical procedure.
Recent research presented at the International Society of Presbyopia 5th Annual Conference demonstrated the ability of FluidVision to restore accommodation. The pilot study included 20 patients who were candidates for cataract surgery and underwent unilateral implantation of the FluidVision lens. Initial results showed excellent distance visual acuity, averaging better than 20/20 at six-month follow-up. Near visual acuity was also excellent at six months, approximately 20/30 when tested unilaterally, a level allowing patients to read without glasses. At six month follow-up, all patients showed at least 3 diopters of accommodation, as measured by the defocus method, with an average of 4.4 diopters. An accommodation range of 2.5 or more diopters should allow patients to see at all distance ranges without glasses.
PowerVision is a private company focused on developing the FluidVision lens, the first "true" accommodating intraocular lens, which has the potential to restore the vision of youth to millions of patients. Accommodation is the eye's ability to adjust to see across a range of distances. The FluidVision lens utilizes natural accommodating forces within the eye to displace fluid in the lens, thereby changing the lens shape and restoring the ability to focus at near and distant targets, as well as all points in between. At this time, PowerVision's products are for investigational use only and are not approved for commercial sale. For more information, visit: http://powervisionlens.com/.